glucagon has been researched along with everolimus in 1 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (everolimus) | Trials (everolimus) | Recent Studies (post-2010) (everolimus) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 5,631 | 1,289 | 4,579 |
| Protein | Taxonomy | glucagon (IC50) | everolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 2 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0022 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baudin, E; Chen, D; Cushman, S; de Vries, EGE; He, W; Pavel, ME; Voi, M; Yao, JC | 1 |
1 trial(s) available for glucagon and everolimus
| Article | Year |
|---|---|
Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Double-Blind Method; Down-Regulation; Everolimus; Female; Gastrins; Glucagon; Humans; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Time Factors; Treatment Outcome; Young Adult | 2017 |